收费全文 | 5826篇 |
免费 | 305篇 |
国内免费 | 8篇 |
2024年 | 13篇 |
2023年 | 86篇 |
2022年 | 125篇 |
2021年 | 312篇 |
2020年 | 147篇 |
2019年 | 166篇 |
2018年 | 183篇 |
2017年 | 156篇 |
2016年 | 272篇 |
2015年 | 296篇 |
2014年 | 311篇 |
2013年 | 469篇 |
2012年 | 424篇 |
2011年 | 460篇 |
2010年 | 263篇 |
2009年 | 236篇 |
2008年 | 320篇 |
2007年 | 287篇 |
2006年 | 260篇 |
2005年 | 216篇 |
2004年 | 200篇 |
2003年 | 169篇 |
2002年 | 168篇 |
2001年 | 47篇 |
2000年 | 41篇 |
1999年 | 39篇 |
1998年 | 30篇 |
1997年 | 32篇 |
1996年 | 18篇 |
1995年 | 27篇 |
1994年 | 28篇 |
1993年 | 22篇 |
1992年 | 18篇 |
1991年 | 17篇 |
1990年 | 15篇 |
1989年 | 19篇 |
1988年 | 17篇 |
1987年 | 18篇 |
1986年 | 8篇 |
1985年 | 24篇 |
1984年 | 21篇 |
1983年 | 15篇 |
1982年 | 25篇 |
1981年 | 13篇 |
1980年 | 16篇 |
1979年 | 9篇 |
1978年 | 13篇 |
1977年 | 10篇 |
1974年 | 6篇 |
1966年 | 7篇 |
MicroRNAs (miRNAs) play important roles in liver pathologies and they are potential biomarkers for diagnosis of liver diseases progression. Changes in miRNA sera expression can be used as non-invasive biomarkers for hepatocellular carcinoma (HCC). The aim of the study was to identify the miRNome profiling of HCC and its diagnostic value in distinguishing HCC from healthy individuals. Expression profiles of miRNAs in serum samples of 20 HCC patients and 10 healthy controls were detected. Whole miRNome profiling was done using next generation sequencing. Receiver operating characteristic (ROC) analysis was performed to assess the diagnostic performance of the deregulated miRNAs for discriminating HCC cases from healthy controls. MiRNA 142 was highly expressed in HCC (P value?=?0.023) while miRNAs 191, 22, and 126 were higher in the controls (P value?=?0.005, 0.034, 0.010 respectively). We have identified 5 novel miRNAs and they were highly expressed in HCC than controls. Analysis of ROC curve demonstrated that these deregulated miRNAs can be used as a reliable biomarker for detection of HCC with high diagnostic accuracy (AUC?=?0.93). We have detected a panel of serum miRNAs that can be used as a reliable noninvasive screening biomarker of HCC. The study recommends further research to shed light on a possible role of the newly discovered novel miRNAs in HCC pathogenesis.
相似文献Matrix metallopeptidase 2 (MMP-2) and matrix metallopeptidase 9 (MMP-9) are involved in the breakdown of extracellular matrix in normal physiological processes as well as in disease processes, such as cancer metastasis. We conducted this work to study the role of MMP-2 and MMP-9 in breast cancer by measuring their plasma concentrations before and after surgery. Also, to examine if their levels can reflect the stage of disease and prognosis. Forty-eight breast cancer patients and 13 patients with benign breast diseases were included in the study. MMP-2 and MMP-9 levels were measured by ELISA and semi-quantitative real-time PCR. MMP-2 and MMP-9 levels in plasma were determined by ELISA immediately before surgery and during 6 to 12 months after curative surgery. We observed a significant increase in the level of MMP-9 mRNA expression in breast cancer patients in comparison to their normal breast tissues and to tissues of benign breast disease. In all TNM tumor stages, the plasma levels of MMP-2 and MMP-9 were increased significantly before curative surgery in the studied patients with breast carcinoma and decreased significantly after surgery. Both MMP-2 and MMP-9 may be used as a possible marker for follow-up or as a marker that reflects the response of the disease to treatment.
相似文献